SCHEMBL6541306

SCHEMBL6541306

Cc1cc(Cl)cc(Cl)c1S(=O)(=O)Nc1ccc(I)c(OCCN(C)C)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PFKFB3 Q16875 1/20 0.41
UTS2R Q9UKP6 4/20 0.41
CHRM2 P08172 1/20 0.38
ADRA2A P08913 1/20 0.38
CHRM1 P11229 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
DRD1 P21728 1/20 0.38
HRH2 P25021 1/20 0.38
HTR1B P28222 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HRH1 P35367 1/20 0.38
DRD3 P35462 1/20 0.38
MCHR2 Q969V1 1/20 0.38
MCHR1 Q99705 1/20 0.38
KDM4E B2RXH2 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
NR3C1 P04150 1/20 0.36
LMNA P02545 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6541270 0.84 PSEN1 (0.44) UTS2RTDP1LMNAHRH3MAPT
SCHEMBL6542141 0.84 UTS2R (0.49) UTS2RKDM4ELMNAALDH1A1KDR
SCHEMBL6543128 0.80 UTS2R (0.47) UTS2RKDM4ELMNAALDH1A1MAPT
SCHEMBL6541433 0.78 KIT (0.43) UTS2RLMNAALDH1A1KDRHRH3
SCHEMBL6542898 0.78 UTS2R (0.51) UTS2RKDM4ETDP1LMNAALDH1A1
SCHEMBL6542040 0.77 CACNA1B (0.46) UTS2RKDM4ELMNAALDH1A1FABP4
SCHEMBL6542131 0.76 CDK1 (0.51) PFKFB3UTS2RTDP1LMNAALDH1A1
SCHEMBL6542508 0.75 UTS2R (0.48) UTS2RHTR1BHTR2AHTR2CDRD3
SCHEMBL7029488 0.75 PFKFB3 (0.59) PFKFB3ADRA2ADRD1HTR1BHTR2A
SCHEMBL7247677 0.75 UTS2R (0.49) UTS2RKDM4ELMNAALDH1A1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1248607-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-10-06 EP claimed
US-20030100580-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-05-29 US claimed
EP-1248607-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-10-16 EP claimed
WO-2001045694-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-28 WO claimed
US-20030100580-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100580-A1 Urotensin-II receptor antagonists UTS2R, TMPRSS4, PLAUR PFKFB3 1557/4885UTS2R 1/4885CHRM2 1393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.